Risk of cardiovascular disease following GnRH agonists versus antagonists in prostate cancer: Real‐world evidence from five databases

Alexandros G.Sfakianakis shared this article with you from Inoreader Risk of cardiovascular disease following GnRH agonists versus antagonists in prostate cancer: Real‐world evidence from five databases Μέσω Int J Cancer ABSTRACT Observational studies in prostate cancer (PCa) have shown an increased risk of cardiovascular disease (CVD) following Gonadotropin‐releasing hormone (GnRH) agonists whereas randomised‐controlled trials have shown no associations. Compared to GnRH agonists, GnRH antagonists have shown less atherosclerotic effects in preclinical models. We used real world data from five countries to investigate CVD risk following GnRH agonists and antagonists in PCa men. Data sources included cancer registries, primary and secondary healthcare databases. CVD event was defined as an incident or fatal CVD. Multivariable Cox proportional hazard models estimated hazard ratios (HR) and 95% confidence intervals (CI) which were pooled using random effects meta‐analysis. Stratified analyses were conducted by history of CVD and age (75 years). 48,757 men were on GnRH agonists and 2,144 on GnRH antagonists. There was no difference in risk of any CVD for men on GnRH antagonists and agonists (HR: 1.25; 95% CI: 0.96‐1.61; I2: 64%). Men on GnRH antagonists showed increased risk of acute myocardial infarction (HR: 1.62; 95% CI: 1.11‐2.35; I2: 0%) and arrhythmia (HR: 1.55; 95% CI: 1.11‐2.15, I2: 17%) compared to GnRH agonists. Having a history of CVD was found to be an effect modifier for the associations with some CVD subtypes. Overall, we did not observe a difference in risk of overall CVD when comparing GnRH antagonists with agonists – though for some subtypes of CVD we noted an increased risk with antagonists. Further studies are required to address potential confounding caused by unadjusted variables such as severity of CVD history and PCa stage View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.